With such a devoted and savvy membership here, it seems somehow disrespectful to even mention money.
So pardon me for saying so, however this stock is, and always has been, a terrible investment. In the world of biotechs it is a well known
fact that the bulk are a mean gamble at best. This one, after holding it for many years, and irrespective of the
"value" of it's underlying drug, it has proven to be the epitome of that fact.
Again, sorry to be crude as to actually mention the $$$ investment part of this ongoing saga.
+Seems almost impolite to speak of here
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: +Seems almost impolite to speak of here
Gwikley, I can offer no counter argument. This has been a terrible investment, but is probably one of the longest surviving independent biotechs and may yet cross the finish line. bp
Re: +Seems almost impolite to speak of here
How darest thou sully the purity of the Cult with thine shameless seeking after mere food, shelter, and medical insurance! Only the highest of the high-born mayest have the honour of sacrificing their inheritance and substance into Geron.
Begone before the Great Old One Rises for the next Call Of Chipthulhu with his message that someday patient screening may begin for yet another monotherapy trial, this one with 1/3 the participants designated for ritual placebo slaughter
Srsly, science and money don't mix inside the twilight of the FDA Zone... look at NBRV, they took a drug that has been in use outside the US for 45 YEARS through yet another Phase 3 trial... and still fell victim to arbitrary FDA sabotage.
Begone before the Great Old One Rises for the next Call Of Chipthulhu with his message that someday patient screening may begin for yet another monotherapy trial, this one with 1/3 the participants designated for ritual placebo slaughter
Srsly, science and money don't mix inside the twilight of the FDA Zone... look at NBRV, they took a drug that has been in use outside the US for 45 YEARS through yet another Phase 3 trial... and still fell victim to arbitrary FDA sabotage.